A randomised double blind placebo controlled trial of infusional subcutaneous octreotide in the management of malignant bowel obstruction in people with advanced cancer.

Full description

Data set includes individual participant data for 112 consenting participants. The dataset includes CSV files for: the number of days free of vomiting as reported by patients daily, measured 72 hours after the first administration of study medication; Patient-rated Global Impression of Change; the number of patient-reported episodes of vomiting; survival as date of death; nausea and Pain scores using NCI CTCAE criteria and Brief Pain Inventory; functional status (Australian modified Karnofsky Performance Scale (AKPS); and; protocol defined “as needed” symptom control medications (hyoscine butylbromide for colicky pain, morphine for pain, haloperidol for nausea). Quality of Life measures used the EORTC C15, Facit Pal and caregiver Quality of life was measured using the Caregiver Quality of Life Index. Data is available for screening, baseline, each day of intervention and 4 weeks of follow-up. Health Service Utilisation data was collected for up to 4 weeks post intervention.

Notes

HeSANDA 1.0.0